- Home
- Mutual Funds
- Tata Mutual Fund
- Tata India Pharma & Healthcare Fund Regular-idcw
Fund Overview of Tata India Pharma & Healthcare Fund Regular-idcw
-
₹1,387.0 CrAUM
-
₹30.19NAV
-
2.22%Expense Ratio
-
EquityFund Category
Minimum amount you can invest: ₹500
Maximum amount you can invest: ₹1,00,000
We have used a return rate of 15% for our calculations.
Returns of Tata India Pharma & Healthcare Fund Regular-idcw
| Tenure | Absolute(%) | Annualised(%) | Category Average(%) |
|---|---|---|---|
| 3 Months | 8.66% | NA | 6.12% |
| 6 Months | 4.68% | NA | 12.92% |
| 1 Year | 6.08% | 6.08% | 6.04% |
| 2 Years | 18.64% | 8.92% | 24.93% |
| 3 Years | 76.92% | 20.95% | 25.71% |
| 5 Years | 87.58% | 13.41% | 19.91% |
| 7 Years | 268.90% | 20.50% | NA |
| 10 Years | 245.58% | 13.20% | 12.78% |
Dividends are declared by the fund house based on the income generated from the underlying assets. While many mutual funds distribute dividends annually, the payout frequency ultimately depends on the fund house’s decision
Compare Tata India Pharma & Healthcare Fund Regular-idcw with other mutual funds in the same category
Tata India Pharma & Healthcare Fund Regular-idcw
SBI Healthcare Opportunities Fund Direct Plan-growth
SBI Healthcare Opportunities Fund Direct Plan-idcw
Asset Allocation
equities
99.30%other assets or cash equivalents
0.70%Tata India Pharma & Healthcare Fund Regular-idcw is one Equity mutual fund offered by Tata Mutual Fund. Launched on 28 Dec 2015, the fund aims Long Term Capital Appreciation. Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India. It manages assets worth ₹1,387.0 crore as on Sun May 31, 2026. The expense ratio stands at 2.22%. Fund Manager Manager EducationAbout Tata India Pharma & Healthcare Fund Regular-idcw
The portfolio allocation consists of 99.30% in equities, 0.70% in other assets or cash equivalents.Managed by Rajat Srivastava, it has delivered a return of 6.08% in the last year, a total return since inception of 11.54%.
The latest dividend was declared on 08 May 2026 at 12.00% of face value.
To take better financial choices it helps to explore best sip investment suited to financial planning needs.
Key Metrics of Tata India Pharma & Healthcare Fund Regular-idcw
-
Standard Deviation17.10%
-
Sharpe Ratio0.94%
-
Alpha-2.76%
-
Beta0.99%
Fund Details
|
|
Top Performing Mutual Funds
| Fund Names | AUM (Cr) | 1M | 3M | 1Yr | 3Yr | 5Yr |
|---|---|---|---|---|---|---|
SBI Healthcare Opportunities Fund Direct Plan-growth  |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹4,566 | 1.67% | 13.30% | 10.49% | 24.74% | 16.80% |
ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth  |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | -1.21% | 11.20% | 7.32% | 26.34% | 16.48% |
| Mirae Asset Healthcare Fund Direct-growth |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| Mirae Asset Healthcare Fund Direct-idcw |
₹3,091 | -0.79% | 9.54% | 13.22% | 24.88% | 15.73% |
| DSP Healthcare Fund Direct-growth |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| DSP Healthcare Fund Direct-idcw |
₹3,309 | 3.03% | 14.21% | 8.50% | 22.68% | 15.62% |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
| SBI Healthcare Opportunities Fund-idcw |
₹4,566 | 1.58% | 13.02% | 9.38% | 23.45% | 15.57% |
growth is based on 1-month returns of the funds & Top fund are based on 3Y Returns
More funds from Tata Mutual Fund
| Fund Names | AUM (Cr) | 1M | 3M | 6M | 1Yr | 3Yr |
|---|---|---|---|---|---|---|
|
Tata India Pharma & Healthcare Fund Regular-growth
|
₹1,387 | -0.88% | 8.66% | 4.68% | 6.08% | 20.95% |
|
Tata India Pharma & Healthcare Fund Direct-growth
|
₹1,387 | -0.76% | 9.05% | 5.42% | 7.62% | 22.73% |
|
Tata India Pharma & Healthcare Fund Direct-idcw
|
₹1,387 | -0.76% | 9.05% | 5.42% | 7.62% | 22.73% |
|
Tata Nifty Midsmall Healthcare Index Fund Regular-growth
|
₹173 | -1.07% | 12.70% | 10.01% | 11.76% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Direct-growth
|
₹173 | -1.01% | 12.87% | 10.34% | 12.44% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Regular-idcw
|
₹173 | -1.07% | 12.70% | 10.01% | 11.76% | - |
|
Tata Nifty Midsmall Healthcare Index Fund Direct-idcw
|
₹173 | -1.01% | 12.87% | 10.34% | 12.44% | - |
growth is based on 1-month returns of the fundsMutual Fund Calculator
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 29
- 31
- 32
- 33
- 34
- 36
- 37
- 38
- 39
- 40
- 1
- 2
- 3
- 4
- 6
- 7
- 8
- 9
- 11
- 12
- 13
- 14
- 16
- 17
- 18
- 19
- 21
- 22
- 23
- 24
- 26
- 27
- 28
- 30
Top Mutual Funds
| Fund Names | AUM (Cr) | NAV | 3Yr | 5Yr | 10Yr |
|---|---|---|---|---|---|
| Nippon India Pharma Fund-growth |
₹8,636 | ₹535.25 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-growth |
₹8,636 | ₹601.05 | 21.51% | 13.66% | 16.24% |
| Nippon India Pharma Fund-idcw |
₹8,636 | ₹115.58 | 20.43% | 12.64% | 15.21% |
| Nippon India Pharma Fund Direct-idcw |
₹8,636 | ₹164.49 | 21.51% | 13.66% | 16.24% |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-growth |
₹6,454 | ₹41.36 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹6,454 | ₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund-idcw |
₹6,454 | ₹24.13 | 25.28% | 15.47% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹6,454 | ₹27.11 | 26.34% | 16.48% | - |
| SBI Healthcare Opportunities Fund-growth |
₹4,566 | ₹468.57 | 23.45% | 15.57% | 13.35% |
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹4,566 | ₹541.52 | 24.74% | 16.80% | 14.59% |
Detailed Portfolio
| Stocks | Sector | % of Holding | Value |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | Healthcare | 9.38% | ₹130.11 Cr |
| Healthcare Global Enterprises Ltd | Healthcare | 5.87% | ₹81.36 Cr |
| Divi's Laboratories Ltd | Healthcare | 5.80% | ₹80.40 Cr |
| Abbott India Ltd | Healthcare | 5.41% | ₹75.07 Cr |
| Cipla Ltd | Healthcare | 5.18% | ₹71.84 Cr |
| Max Healthcare Institute Ltd | Healthcare | 4.80% | ₹66.64 Cr |
| Apollo Hospitals Enterprise Ltd | Healthcare | 4.56% | ₹63.24 Cr |
| Rainbow Childrens Medicare Ltd | Healthcare | 4.52% | ₹62.71 Cr |
| Dr. Reddy's Laboratories Ltd | Healthcare | 4.02% | ₹55.80 Cr |
| Mankind Pharma Ltd. | Healthcare | 3.77% | ₹52.27 Cr |
| Fortis Healthcare Ltd | Healthcare | 3.41% | ₹47.29 Cr |
| Glaxosmithkline Pharmaceuticals Ltd | Healthcare | 3.26% | ₹45.25 Cr |
| Bayer Cropscience Ltd | Materials | 3.10% | ₹43.06 Cr |
| Lupin Ltd | Healthcare | 2.76% | ₹38.27 Cr |
| Sai Life Sciences Ltd. | Healthcare | 2.73% | ₹37.81 Cr |
| Syngene International Ltd | Healthcare | 2.65% | ₹36.82 Cr |
| Alkem Laboratories Ltd | Healthcare | 2.42% | ₹33.61 Cr |
| Jb Chemicals & Pharmaceuticals Ltd | Healthcare | 2.24% | ₹31.03 Cr |
| Global Health Ltd | Healthcare | 2.20% | ₹30.50 Cr |
| Fdc Ltd | Healthcare | 2.12% | ₹29.38 Cr |
Top Equity Funds
| Fund Names | NAV | 3Yr | 5Yr | 52 weeks high |
|---|---|---|---|---|
| SBI Healthcare Opportunities Fund Direct Plan-growth |
₹541.52 | 24.74% | 16.80% | - |
| SBI Healthcare Opportunities Fund Direct Plan-idcw |
₹376.23 | 24.74% | 16.80% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-growth |
₹44.89 | 26.34% | 16.48% | - |
| ICICI Prudential Pharma Healthcare And Diagnostics (p.h.d) Fund Direct-idcw |
₹27.11 | 26.34% | 16.48% | - |
| Mirae Asset Healthcare Fund Direct-growth |
₹47.24 | 24.88% | 15.73% | - |
| Mirae Asset Healthcare Fund Direct-idcw |
₹28.45 | 24.88% | 15.73% | - |
| DSP Healthcare Fund Direct-growth |
₹46.19 | 22.68% | 15.62% | - |
| DSP Healthcare Fund Direct-idcw |
₹26.71 | 22.68% | 15.62% | - |
| SBI Healthcare Opportunities Fund-growth |
₹468.57 | 23.45% | 15.57% | - |
| SBI Healthcare Opportunities Fund-idcw |
₹295.17 | 23.45% | 15.57% | - |
growth is based on 5Y returns of the funds
Frequently Asked Questions
Tata India Pharma & Healthcare Fund Regular-idcw
What is the current AUM of Tata India Pharma & Healthcare Fund Regular-idcw?
As of Sun May 31, 2026, Tata India Pharma & Healthcare Fund Regular-idcw manages assets worth ₹1,387.0 crore
How has Tata India Pharma & Healthcare Fund Regular-idcw performed recently?
- 3 Months: 8.66%
- 6 Months: 4.68%
What is the long-term performance of Tata India Pharma & Healthcare Fund Regular-idcw?
- 3 Years CAGR: 20.95%
- 5 Years CAGR: 13.41%
- Since Inception: 11.54%
What is the portfolio composition of Tata India Pharma & Healthcare Fund Regular-idcw?
Equity: 99.30%, Others: 0.70%.
Who manages Tata India Pharma & Healthcare Fund Regular-idcw?
Tata India Pharma & Healthcare Fund Regular-idcw is managed by Rajat Srivastava from Tata Mutual Fund.
When was the last dividend declared by Tata India Pharma & Healthcare Fund Regular-idcw?
Latest dividend was declared on 08 May 2026 at 12.00% of face value.
What is the market-cap allocation of Tata India Pharma & Healthcare Fund Regular-idcw?
Large Cap: 35.41%, Mid Cap: 23.76%, Small Cap: 40.83%.
Which are the top companies Tata India Pharma & Healthcare Fund Regular-idcw has invested in?
- Sun Pharmaceutical Industries Ltd – 9.38% of the fund's portfolio
- Healthcare Global Enterprises Ltd – 5.87% of the fund's portfolio
- Divi's Laboratories Ltd – 5.80% of the fund's portfolio
- Abbott India Ltd – 5.41% of the fund's portfolio
- Cipla Ltd – 5.18% of the fund's portfolio
Which are the major sectors Tata India Pharma & Healthcare Fund Regular-idcw focuses on?
- Healthcare – 77.10% of the fund's portfolio
- Materials – 3.10% of the fund's portfolio
Policybazaar does not endorse rates/returns or recommend any particular insurer, fund house, AMC (Asset Management Company), insurance and mutual fund product.
Please consult your financial advisor for an informed decision.
Past performance may not be indicative of future results.
The information presented on this page is not owned or generated by Policybazaar. The data has been collected from publicly available sources and online research. We do not claim any ownership or guarantee the accuracy, completeness, or timeliness of this information. It is shared solely for the informational purpose of the viewer and should not be considered as financial advice.
Policybazaar is not acting as a financial advisor, broker, or agent for any mutual fund mentioned here.
Mutual fund investments are subject to market risks. Please read all scheme-related documents carefully before investing.
Policybazaar shall not be held responsible or liable for any losses, damages, or decisions made based on the information provided on this page.
For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product. For a complete list of mutual funds registered in India, please refer to the Securities and Exchange Board of India (SEBI) website at www.sebi.gov.in. We do not sell, endorse, or recommend any mutual fund or investment product.
For more details on risk factors, terms, and conditions, please read the sales brochure and benefit illustration carefully before concluding a sale.
Policybazaar is a registered Insurance Broker | Registration No. 742, Registration Code No. IRDA/ DB 797/ 19, Valid till 09/06/2024, License category- Direct Broker (Life & General) |CIN: U74999HR2014PTC053454 | Registered Office - Plot No.119, Sector - 44, Gurgaon, Haryana – 122001 |Visitors are hereby informed that their information submitted on the website may be shared with insurers. Product information is authentic and solely based on the information received from the insurers.©️ Copyright 2008-2025 policybazaar.com. All Rights Reserved
^Returns as on 10th Jan’25. Tata AIA Life Top 200 ULIP Fund has delivered 18% returns over the last 10 years. Past performance is not necessarily indicative of future results. This disclaimer is specifically regarding a ULIP fund and is not related to mutual funds. Source: Morningstar.
